Mark K. Greenwald (aa2678)
University information
Contact information
Division of Nicotine and Tobacco Research
Dr. Greenwald’s research focuses on the pharmacological, environmental, and individual difference determinants of drug-seeking behavior including nicotine. Recent work has focused on the effects of stress on nicotine seeking and brain function (Woodcock et al. 2019a, 2019b), and future work is expected to focus on therapeutic approaches including medications and neuromodulation.
Psychiatry and Behavioral Neurosciences
Professor and Associate Chair for Research
Tolan Park
Detroit, MI 48201
Suite 2A, Room 225
Dr. Greenwald directs the Substance Abuse Research Division, its Human Pharmacology Laboratory and the outpatient treatment research clinic in the Department of Psychiatry and Behavioral Neurosciences at Wayne State University. He previously directed the Ph.D. training program in Translational Neuroscience at the WSU School of Medicine. The National Institute on Drug Abuse (NIDA) has continuously funded his research since 1996. He has been the principal investigator and a co-investigator on many federally funded grants, and regularly reviews manuscripts for many substance abuse related journals and federal grant applications.
Oberlin College, Oberlin, OH, 1983, B.A. (Psychology), Cum laude.1978 - 1983
Oberlin Conservatory of Music, Oberlin, OH, 1983, B.M. (Music Composition)
University of Florida, Gainesville, FL, 1987, M.S. (Clinical & Health Psychology) 1983 - 1992
University of Florida, Gainesville, FL, 1992, Ph.D. (Experimental Psychology)
Postgraduate Training
Research Fellow, Behavioral Pharmacology Research Unit, Dept. of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. 1994 - 1995
Research Fellow, Addiction Research Center, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD. 1992 - 1994
- Substance use disorders
- Psychopharmacology
- Determinants of drug use
- Development of addiction treatments
- Brain imaging
Translational Neuroscience Program
Pharmacological, environmental and individual difference determinants of drug-seeking/use behavior (primary endpoint) and neural processes (measured with in vivo imaging methods) related to these behaviors.
Disease/Disorder
Opioid, cocaine, marijuana, nicotine, and alcohol use disorders.
Species
Human
Methods
PET (opioid and dopamine), 1H spectroscopy, fMRI and EEG.
Key Collaborators
Leslie Lundahl, David Ledgerwood and Cynthia Arfken (substance use disorders, HIV/AIDS); Jeffrey Stanley (1H spectroscopy); Vaibhav Diwadkar (fMRI, learning/memory); Sylvie Naar-King and Paul Burghardt (stress, physical activity and obesity); Terrance Albrecht, Ann Schwartz and Jennifer Beebe-Dimmer (KCI: chemotherapy-induced peripheral neuropathy); Timothy Roehrs (Henry Ford: EEG, sleep, pain); Margit Burmeister (Univ. of Michigan: pharmacogenetics).
